Falcigo Plus is a fixed-dose combination tablet containing 100 mg of Artesunate and 200 mg of Mefloquine. It is primarily used for the treatment of uncomplicated malaria caused by Plasmodium falciparum, including multidrug-resistant strains. Learn more about malaria and its treatment on Mayo Clinic and WHO.

Key Benefits & Uses

• Effective Treatment: Combines Artesunate and Mefloquine for rapid and sustained action against P. falciparum (Drugs.com).

• Simplified Dosing: Fixed-dose tablets improve adherence, reducing the risk of incomplete treatment (WebMD).

• Wide Age Range: Suitable for adults and children above 7 years, under medical supervision (Healthline).

How to Use
Take Falcigo Plus orally with or without food, following the exact dosage prescribed by your healthcare provider. Avoid crushing or chewing the tablet. Taking it consistently at the same time each day helps maintain effective blood levels (Mayo Clinic).

Important Safety Information
Do not use Falcigo Plus if allergic to Artesunate, Mefloquine, or any component of the tablet. Inform your doctor if you have a history of liver disease, heart conditions, or psychiatric disorders. Pregnant or breastfeeding women should consult their healthcare provider. Be aware of potential drug interactions; concurrent use with certain medications may increase risks (FDA, PubMed).

Common Side Effects
Mild side effects may include nausea, vomiting, diarrhea, dizziness, headache, insomnia, or vivid dreams (Mayo Clinic, Healthline). Psychiatric effects like anxiety or depression can occur rarely. Most side effects are transient, but seek medical attention if symptoms persist.

Why Choose Falcigo Plus
Falcigo Plus combines the rapid action of Artesunate with the long-lasting effect of Mefloquine, offering a comprehensive solution for P. falciparum malaria. Its fixed-dose regimen simplifies treatment and enhances adherence. Manufactured by Zydus Cadila, a trusted pharmaceutical company, it ensures reliable quality and therapeutic effectiveness (WHO).